| 1.62 -0.03 (-1.82%) | 10-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.1 | 1-year : | 2.45 |
| Resists | First : | 1.79 | Second : | 2.1 |
| Pivot price | 1.61  |
|||
| Supports | First : | 1.46 | Second : | 1.25 |
| MAs | MA(5) : | 1.68 |
MA(20) : | 1.54 |
| MA(100) : | 1.94 |
MA(250) : | 2.16 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 66 |
D(3) : | 76.3 |
| RSI | RSI(14): 51.3 |
|||
| 52-week | High : | 5 | Low : | 1.1 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AUTL ] has closed below upper band by 48.5%. Bollinger Bands are 49.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.65 - 1.66 | 1.66 - 1.67 |
| Low: | 1.55 - 1.57 | 1.57 - 1.58 |
| Close: | 1.6 - 1.62 | 1.62 - 1.64 |
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Tue, 16 Sep 2025
Zero Grade 2+ Side Effects: Autolus' Revolutionary CAR-T Treatment Shows Promise in Lupus Patients - Stock Titan
Tue, 12 Aug 2025
Autolus Therapeutics: Expanding The Reach Of Its CD19 Therapy, But Still Far From Profitable - Seeking Alpha
Mon, 11 Aug 2025
Autolus Therapeutics PLC (AUTL) Q2 2025 Earnings Report Preview: What To Look For - GuruFocus
Thu, 24 Jul 2025
Autolus Therapeutics plc Announces Q2 2025 Financial Results Release Date and Conference Call Details - Nasdaq
Tue, 15 Jul 2025
Autolus Awards Massive Stock Options Package: 360K Shares Granted to 60 New Employees Under Nasdaq Rule - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 266 (M) |
| Shares Float | 119 (M) |
| Held by Insiders | 18 (%) |
| Held by Institutions | 80.9 (%) |
| Shares Short | 11,490 (K) |
| Shares Short P.Month | 10,110 (K) |
| EPS | -0.88 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.29 |
| Profit Margin | 0 % |
| Operating Margin | -292.6 % |
| Return on Assets (ttm) | -21.5 % |
| Return on Equity (ttm) | -52.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.59 |
| Sales Per Share | 0.11 |
| EBITDA (p.s.) | -0.99 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -263 (M) |
| Levered Free Cash Flow | -238 (M) |
| PE Ratio | -1.87 |
| PEG Ratio | 0 |
| Price to Book value | 1.24 |
| Price to Sales | 14.4 |
| Price to Cash Flow | -1.64 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|